Regulation 13

a reference to an EV charger is a reference to the specified EV charger;

the references in sections 35(1), (2)(c), (4), (5) and (6) and 37(2)(a) to a manufacturer or supplier of an EV charger are references to the person who supplied the specified EV charger to the specified person;

the reference in section 35(1) to the time prescribed is a reference to 7 calendar days;

section 35(1)(b) and (c) is replaced with a reference to the specified person;

the reference in section 35(3) to a person to whom the notice is addressed is a reference to the specified person;

section 35(3)(b) does not apply;

the reference in section 35(5) to the prescribed time is a reference to 14 calendar days or any longer time that the LTA may by written notice allow;

the reference in section 36(1) to a person in section 35(1)(b) or (c) is a reference to the specified person;

section 37(2)(b), (c) and (d) is replaced with a reference to the specified person;

the reference in section 38(1) to the person or class of persons is a reference to the specified person;

the reference in section 38(2) to a person is a reference to the specified person;

section 38(3), (4), (5) and (6)(b) and (c) does not apply;

the reference in section 39(1) to the person bound by a safety and security directive is a reference to the specified person;

the reference in section 39(2) to a person to whom a safety and security directive is given is a reference to the specified person.

a reference to the granting of a licence to any person is a reference to the granting of an authorisation to the specified person to undertake the approved trial;

a reference to the licensee is a reference to the specified person;

a reference to the validity period of the licence is a reference to the specified period;

a reference to approved policies is a reference to policies of insurance each of which is not subject to any conditions, exclusions or exceptions prohibited by these Rules;

a reference to the regulated activity authorised by the licence is a reference to the approved trial.